Constitutive modelling of polylactic acid at large deformation using multiaxial strains

YesSheet specimens of a PLLA-based polymer have been extended at a temperature near to the glass transition in both uniaxial and planar tension, with stress relaxation observed for some time after reaching the final strain. Both axial and transverse stresses were recorded in the planar experiments. In all cases during loading, yielding at small strain was followed by a drop in true stress and then strain hardening. This was followed by stress relaxation at constant strain, during which stress dropped to reach an effectively constant level. Stresses were modelled as steady state and transient components. Steady-state components were identified with the long-term stress in stress relaxation and associated with an elastic component of the model. Transient stresses were modelled using Eyring mechanisms. The greater part of the stress during strain hardening was associated with dissipative Eyring processes. The model was successful in predicting stresses in both uniaxial and planar extension over a limited range of strain rate

Microinjection moulded polyetheretherketone biomaterials as spinal implants: physico-chemical and mechanical characterisation

YesPolyetheretherketone (or PEEK) is a thermoplastic polymer known for its high plasticity and toughness and has been widely employed as a material for a variety of load-bearing medical devices ranging from trauma implants to interspinal spacers and femoral stems. While being inherently chemically inert and therefore biocompatible and having very short lived post-radiation free radicals, PEEK presents different mechanical properties depending on its degree of crystallinity. It can be processed via extrusion, injection or compression moulding. However, these techniques do not allow high precision control over the fine morphological structure that strongly influences mechanical properties. Microinjection moulding, in contrast, makes it possible to produce fine details of medical implants with high precision and accuracy. Another advantage of this method is the controlled production of the material with heterogeneous structure due to variations in crystallinity. Having stiffness in the middle of the sample different from that at the edges enables a structure that mimics the bone/cartilage parts of an implant. This paper reports on the manufacturing of PEEK components by microinjection moulding, and their characterisation by physico-chemical (XRD, SAXS, TEM, FTIR, POM) and mechanical (tensile testing) means, in order to assess the suitability of use for biomedical application, such as spinal implants. We discuss the influence of such parameters as mould temperatures, injection speeds and hold pressures on the crystallinity and mechanical properties of the material.Science Bridges: Bradford-China Programme for Pharmaceutical Sciences and Medical Technology, EP/G042365/

Nanoindentation analysis of oriented polypropylene: Influence of elastic properties in tension and compression

YesPolypropylene has been oriented by solid-phase deformation processing to draw ratios up to ∼16, increasing tensile stiffness along the draw direction by factors up to 12. Nanoindentation of these materials showed that moduli obtained for indenter tip motion along the drawing direction (3) into to 1–2 plane (axial indentation) were up to 60% higher than for indenter tip motion along the 2 direction into the 1–3 plane (transverse indentation). In static tests, tensile and compressive determinations of elastic modulus gave results differing by factors up to ∼5 for strain along the draw direction. A material model incorporating both orthotropic elasticity and tension/compression asymmetry was developed for use with Finite Element simulations. Elastic constants for the oriented polypropylene were obtained by combining static testing and published ultrasonic data, and used as input for nanoindentation simulations that were quantitatively successful. The significance of the tension/compression asymmetry was demonstrated by comparing these predictions with those obtained using tensile data only, which gave predictions of indentation modulus higher by up to 70%

Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue

Five-year survival for patients with oral cancer has been disappointingly stable during the last decades, creating a demand for new biomarkers and treatment targets. Lately, much focus has been set on immunomodulation as a possible treatment or an adjuvant increasing sensitivity to conventional treatments. The objective of this study was to evaluate the prognostic importance of response to radiotherapy in tongue carcinoma patients as well as the expression of the CXC-chemokines in correlation to radiation response in the same group of tumours. Thirty-eight patients with tongue carcinoma that had received radiotherapy followed by surgery were included. The prognostic impact of pathological response to radiotherapy, N-status, T-stage, age and gender was evaluated using Cox's regression models, Kaplan-Meier survival curves and chi-square test. The expression of 23 CXC-chemokine ligands and their receptors were evaluated in all patients using microarray and qPCR and correlated with response to treatment using logistic regression. Pathological response to radiotherapy was independently associated to overall survival with a 2-year survival probability of 81 % for patients showing a complete pathological response, while patients with a non-complete response only had a probability of 42 % to survive for 2 years (p = 0.016). The expression of one CXC-chemokine, CXCL10, was significantly associated with response to radiotherapy and the group of patients with the highest CXCL10 expression responded, especially poorly (p = 0.01). CXCL10 is a potential marker for response to radiotherapy and overall survival in patients with squamous cell carcinoma of the tongue

The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

Abstract: Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites.“To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altma

The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised.This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process.The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text.The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites."To maximise the benefit to society, you need to not just do research but do it well" Douglas G Altman

Introducing BASE: the Biomes of Australian Soil Environments soil microbial diversity database

Background: Microbial inhabitants of soils are important to ecosystem and planetary functions, yet there are large gaps in our knowledge of their diversity and ecology. The 'Biomes of Australian Soil Environments' (BASE) project has generated a database of microbial diversity with associated metadata across extensive environmental gradients at continental scale. As the characterisation of microbes rapidly expands, the BASE database provides an evolving platform for interrogating and integrating microbial diversity and function. Findings: BASE currently provides amplicon sequences and associated contextual data for over 900 sites encompassing all Australian states and territories, a wide variety of bioregions, vegetation and land-use types. Amplicons target bacteria, archaea and general and fungal-specific eukaryotes. The growing database will soon include metagenomics data. Data are provided in both raw sequence (FASTQ) and analysed OTU table formats and are accessed via the project's data portal, which provides a user-friendly search tool to quickly identify samples of interest. Processed data can be visually interrogated and intersected with other Australian diversity and environmental data using tools developed by the 'Atlas of Living Australia'. Conclusions: Developed within an open data framework, the BASE project is the first Australian soil microbial diversity database. The database will grow and link to other global efforts to explore microbial, plant, animal, and marine biodiversity. Its design and open access nature ensures that BASE will evolve as a valuable tool for documenting an often overlooked component of biodiversity and the many microbe-driven processes that are essential to sustain soil function and ecosystem services

Introducing BASE: the Biomes of Australian Soil Environments soil microbial diversity database

Microbial inhabitants of soils are important to ecosystem and planetary functions, yet there are large gaps in our knowledge of their diversity and ecology. The ‘Biomes of Australian Soil Environments’ (BASE) project has generated a database of microbial diversity with associated metadata across extensive environmental gradients at continental scale. As the characterisation of microbes rapidly expands, the BASE database provides an evolving platform for interrogating and integrating microbial diversity and function